Caribou Biosciences, Inc. (Nasdaq: CRBU), a prominent clinical-stage biopharmaceutical company specializing in CRISPR genome editing, has announced a webcast scheduled for 8:00 AM ET on November 3, 2025. During this event, the company will provide updates on new data from two important clinical trials involving allogeneic CAR-T cell therapies.
The webcast will feature findings from the ANTLER phase 1 clinical trial, which focuses on vispacabtagene regedleucel (vispa-cel; previously known as CB-010). This therapy is being evaluated for its effectiveness in patients suffering from relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). In addition, the presentation will include the first clinical data from the CaMMouflage Phase 1 trial, assessing CB-011, an allogeneic anti-BCMA CAR-T cell therapy designed for patients with relapsed or refractory multiple myeloma (r/r MM).
Alongside these updates, the company plans to discuss the anticipated design of its pivotal phase 3 trial for vispa-cel and outline the next steps for the ongoing clinical development of CB-011. Interested parties can access the live webcast through the Events page on Caribou”s official website, with an archived version available for 30 days post-event.
Vispacabtagene regedleucel is notable for being the first allogeneic CAR-T cell therapy in clinical trials that incorporates a PD-1 knockout. This innovative genome-editing approach is intended to enhance the activity of CAR-T cells by preventing premature exhaustion. The FDA has recognized vispa-cel with several designations, including Regenerative Medicine Advanced Therapy (RMAT), Orphan Drug, and Fast Track for B-NHL. Additional details regarding the ANTLER trial can be accessed at clinicaltrials.gov under the identifier NCT04637763.
CB-011 is also a pioneering therapy, engineered to maintain its effectiveness through an immune cloaking mechanism that employs a B2M knockout and the introduction of a B2M–HLA-E fusion protein. This design seeks to mitigate immune-mediated rejection in patients with r/r MM. The FDA has bestowed Fast Track and Orphan Drug designations upon CB-011 as well. More information on the CaMMouflage trial can be found at clinicaltrials.gov under the identifier NCT05722418.
Caribou Biosciences, Inc. is focused on advancing transformative therapies using its CRISPR genome-editing platform, which features the Cas12a chRDNA technology. This platform aims for superior precision in developing cell therapies that could significantly enhance treatment outcomes for patients battling serious diseases. The company is committed to advancing vispacabtagene regedleucel and CB-011 as off-the-shelf CAR-T cell therapies that promise broad accessibility and expedited treatment for patients facing hematologic malignancies.
For further updates, follow the company on social media at @CaribouBio and visit their website at www.cariboubio.com.
For inquiries, please contact Peggy Vorwald, PhD, at [email protected].
